AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI) Achieves Clinical Remission And Endoscopic Response At Week 12 In Patients With Moderate To Severe Crohn's Disease
Portfolio Pulse from Benzinga Newsdesk
AbbVie has presented new data showing that its drug Risankizumab (SKYRIZI) achieves clinical remission and endoscopic response at week 12 in patients with moderate to severe Crohn's Disease.
May 24, 2021 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's drug SKYRIZI has shown positive results in clinical trials for Crohn's Disease, potentially boosting the company's product portfolio and stock price.
The positive clinical trial results for SKYRIZI in treating Crohn's Disease could enhance AbbVie's product offerings and market position, likely leading to a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90